Compare TNET & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | EWTX |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2000 | 2021 |
| Metric | TNET | EWTX |
|---|---|---|
| Price | $68.75 | $44.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $65.80 | $39.00 |
| AVG Volume (30 Days) | 421.7K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $5,010,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | $22.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.67 | $13.53 |
| 52 Week High | $73.08 | $48.40 |
| Indicator | TNET | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 55.97 |
| Support Level | $55.63 | $37.50 |
| Resistance Level | $73.08 | $44.93 |
| Average True Range (ATR) | 3.60 | 2.17 |
| MACD | -0.49 | 0.11 |
| Stochastic Oscillator | 51.58 | 75.25 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.